Press Release
G2GBio has the best subject matter experts in the field of the injectable drug development.
-
G2GBIO signs agreement with China's UBT to evaluate 'sustained-effecti..G2GBIO signs agreement with China's UBT to evaluate 'sustained-effective injectable' developme..
2026.10.23 -
G2G Bio Unveils Ultra-High-Concentration Antibody Formulation for Subc..G2G Bio Unveils Ultra-High-Concentration Antibody Formulation for Subcutaneous InjectionsG2G Bio ..
2026.10.21 -
G2GBIO secures PK data for high-dose once-monthly dementia injectable ..G2GBIO secures PK data for high-dose once-monthly dementia injectable – “Steady-state at 280mg..
2026.09.09 -
G2GBIO confirms safety and tolerability of multiple doses for Alzheime..G2GBIO confirms safety and tolerability of multiple doses for Alzheimer's drug candidate 'GB-5001' i..
2026.09.09 -
[Interview] G2GBIO Expands Beyond Long-Acting Drug Delivery Technology..[Interview] G2GBIO Expands Beyond Long-Acting Drug Delivery Technology into Antibody SC Formulations..
2026.08.07 -
G2GBIO teams up with Celltrion to develop ultra-concentrated antibody ..G2GBIO teams up with Celltrion to develop ultra-concentrated antibody SC formulations - Applica..
2026.08.07 -
G2GBIO reports first preclinical results for long-acting injectable..- Findings presented at the Schizophrenia International Research Society (SIRS) conference held l..
2026.04.09 -
G2GBIO CEO Lee Hee-yong: 30 Years of dedication to microspheres leads ..- Engineering the ‘Time of Effect’…Microspheres redefine the future of treatment strategies- F..
2026.04.09